Moderna Announces New Supply Agreement with Switzerland for Additional Seven Million Doses of COVID-19 Booster Vaccine
These doses are in addition to the seven million doses of Moderna's booster vaccine that are scheduled for supply to Switzerland in the second half of 2022, which the Government exercised its option to purchase in December 2021.;
Cambridge: Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for seven million doses of Moderna's COVID-19 booster vaccine for anticipated delivery in 2023 and an additional option of seven million doses for delivery in 2023 and 2024.
These doses are in addition to the seven million doses of Moderna's booster vaccine that are scheduled for supply to Switzerland in the second half of 2022, which the Government exercised its option to purchase in December 2021.
"We thank the Swiss Federal Government for their trust in our mRNA COVID-19 vaccine and for its leadership in preparing for an endemic setting in 2023 and 2024," said Stéphane Bancel, Moderna's Chief Executive Ocer. "COVID-19 booster doses will continue to be instrumental in keeping infection rates down in our communities as we continue our ght against the pandemic."
SPIKEVAX (elasomeran mRNA vaccine) has been granted approval by Swissmedic and is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older.
Read Also - Moderna submits amendment to USFDA for its COVID-19 vaccine booster dose
Moderna has transformed from a science research-stage company advancing programs in the eld of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-eective vaccines against the COVID-19 pandemic.
Read Also - Moderna to set RNA vaccine manufacturing facility in Kenya
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.